rifampin and Neuritis

rifampin has been researched along with Neuritis* in 10 studies

Reviews

1 review(s) available for rifampin and Neuritis

ArticleYear
[Adverse effects of antitubercular agents].
    Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases, 1985, Volume: 8, Issue:6

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hearing Loss, Bilateral; Humans; Immune Complex Diseases; Isoniazid; Neuritis; Rifampin; Streptomycin

1985

Trials

3 trial(s) available for rifampin and Neuritis

ArticleYear
Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2001, Volume: 69, Issue:3

    This paper aims to describe the histomorphologic features of skin biopsies of single lesion leprosy patients recruited at outpatient clinics in four Brazilian states in the Northeast (Amazonas and Rondonia), Southeast (Rio de Janeiro) and Center-West (Goiás) between October 1997 and December 1998. Patients clinically diagnosed as single skin lesion paucibacillary (SSL-PB) leprosy had a standard 4-mm punch biopsy taken from the lesion before rifampin, ofloxacin, minocycline (ROM) therapy. The features of the cellular inflammatory infiltrates, the presence of nerve involvement and acid-fast bacilli (AFB) were used to categorize SSL-PB biopsies into different histopathological groups. Two-hundred-seventy-eight (93.0%) out of 299 patients had a skin biopsy available. Seven single lesion patients were diagnosed as BL or LL leprosy types (MB) by the histopathological exams and 12 cases were excluded due to other skin diseases. Therefore, 259 patients had skin lesions with histomorphological features compatible with PB leprosy categorized as follows: 33.6% (N = 87) of the biopsies represented well-circumscribed epithelioid cell granuloma (Group 1); 21.6% (N = 56) less-circumscribed epithelioid cell granuloma (Group 2); 12.0% (N = 31) were described as mononuclear inflammatory infiltrate permeated with epithelioid cells (Group 3), and 29.7% (N = 77) had perivascular/periadnexal mononuclear inflammatory infiltrate (Group 4). Minimal/no morphological alteration in the skin was detected in only 8 (3.1%) SSL-PB patients categorized as Group 5, who were considered to have leprosy by clinical parameters. SSL-PB leprosy patients recruited in a multicentric study presented histomorphology readings comprising the whole PB leprosy spectrum but also a few MB cases. These results indicate heterogeneity among SSL-PB patients, with a predominance of well-circumscribed and less-circumscribed epithelioid cell granulomas (Groups 1 and 2) in the sites studied and the heterogeneity of local cellular immune response.

    Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Cohort Studies; Drug Therapy, Combination; Female; Histocytochemistry; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Middle Aged; Minocycline; Mycobacterium leprae; Neuritis; Ofloxacin; Rifampin

2001
Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2000, Volume: 68, Issue:4

    Forty-six, newly detected, previously untreated multibacillary (MB) patients with a bacterial index (BI) of > or = 3+ who had received WHO/MDT for 2 years were followed up for a total duration of 424 person-years and a mean duration of 9.26 +/- 2.98 years per patient. The BIs of the patients continued to fall, and all of the patients, except one, reached skin-smear negativity. WHO/MDT was well accepted and well tolerated. Relapse, which was defined as an increase in the BI of 1+ or more with or without clinical evidence of activity, was observed in only one patient, giving a relapse rate of 2.2% or 0.23 per 100 person-years in patients with a BI of > or = 3+ after long-term follow up. This patient was started on a second course of WHO/MDT to which he responded favorably. WHO/MDT for a fixed duration of 2 years for MB patients as recommended by the WHO is vindicated.

    Topics: Adult; Clofazimine; Cohort Studies; Dapsone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leprostatic Agents; Leprosy; Male; Neuritis; Recurrence; Rifampin; World Health Organization

2000
Reversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w.
    Leprosy review, 1993, Volume: 64, Issue:3

    Immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w, was given in addition to standard multidrug therapy (MDT) to 53 multibacillary lepromin negative patients belonging to BB, BL and LL types of leprosy (vaccine group). An equal control group received MDT and injections of micronized starch as placebo. Both the vaccine and placebo were administered intradermally every 3 months. The patients were evaluated at determined intervals by clinical, bacteriological and histopathological parameters and lepromin testing. Reactional episodes were analysed with reference to incidence, onset, frequency and severity during and after release from treatment (RFT). Incidence of reversal reaction (RR) was marginally higher in the vaccine group (22.6% vaccine group vs 15% control group). All cases with a history of downgrading type 1 reaction developed RR during therapy. Most episodes occurred within the 1st year of the commencement of therapy--50% developing within 3 months. Late reversal reaction (after RFT) were observed in 3.8% of cases in both groups, and 50% of the reactors in the control group and 33% in the vaccine group had repeated reactional episodes. Incidence of neuritis associated with RR as well as isolated neuritis was similar in both groups.

    Topics: Bacterial Vaccines; Clofazimine; Combined Modality Therapy; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Neuritis; Rifampin; Single-Blind Method

1993

Other Studies

6 other study(ies) available for rifampin and Neuritis

ArticleYear
Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study.
    Journal of chemotherapy (Florence, Italy), 2023, Volume: 35, Issue:5

    Linezolid (LZD) is an effective drug in treating multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. This study aimed to evaluate the safety of LZD in the treatment of patients with rifampicin resistant tuberculosis. This was a multicenter retrospective study. A total of 184 patients of the rifampicin resistant tuberculosis patients treated with LZD from Jan 2018 to Apr 2020 in three hospitals were involved, and their clinical symptoms were recorded and analyzed. Meanwhile, the types and incidence of adverse effects associated with LZD were evaluated. It showed that peripheral neuritis (51, 27.7%) and hemochromatosis (42, 22.8%) were the most common adverse effects observed among these patients. The median time of symptoms after LZD treatment was 45.5 and 120.0 days, respectively. Furthermore, female patients had a significantly higher risk for leukopenia (P = 0.002) and hemochromatosis (P = 0.033) when compared with male patients. History of underlying disease was the risk factor for thrombocytopenia (P = 0.022). Patients with long duration of medication (RR = 1.004, 95%CI: 1.002-1.006, P < 0.001) and daily dosage ≥600mg (RR = 3.059, 95%CI: 1.238-7.558, P = 0.015) were at higher risk of hemochromatosis. Age was the risk factor for rash (P = 0.008) and nausea and vomiting (P = 0.018). In addition, LZD administration time was the risk factor for optic neuritis (P < 0.001) and peripheral neuritis (P < 0.001). LZD can cause adverse symptoms in patients with rifampicin resistant tuberculosis. Gender, history of underlying disease, LZD use time, LZD dosage, and age are the risk factors in the LZD treatment of these patients. During medication, bone marrow suppression and neuropathy should be closely monitored. This study could potentially provide useful information for the clinical practice.

    Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hemochromatosis; Humans; Linezolid; Male; Neuritis; Retrospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant

2023
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:7

    Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromatous; Neuritis; Nevirapine; Rifampin; Senegal; Stavudine; Tinea Capitis

2011
[Patient with Hansen disease and lepromatous reaction with predominant neural involvement].
    Neurologia (Barcelona, Spain), 1998, Volume: 13, Issue:1

    We describe a patient with a diagnosis of Hansen's disease borderline type, presenting as cutaneous lesions and silent multineuritis. Samples of nasal mucus, earlobe and cutaneous lesions were positive for acid-fast bacilli. He was given treatment with rifampin, dapsone and clofazimine. Five years later, he developed fever, poliarthritis, orchitis and hepatic involvement. Searching for acid-fast bacilli in many cutaneous and mucosal locations was fruitfulness. Because of clinical suspicion of erythema nodosum leprosum, he was treated with steroids with improvement of his clinical picture, but subsequently he developed multineuritis with many sensitive symptoms. A high number of bacilli was seen in nerve biopsy. We comment on atypical features of clinical evolution and erythema nodosum leprosum, and emphasize the significance of large number of bacilli into peripheral nerve in contrast with their absence at other levels.

    Topics: Biopsy; Clofazimine; Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Middle Aged; Neuritis; Peripheral Nerves; Rifampin

1998
Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1986, Volume: 54, Issue:2

    A systematic study was performed on the reactions occurring during several short-course therapy regimens for the treatment of paucibacillary and multibacillary patients. Most type 1 upgrading reactions in paucibacillary (PB) leprosy were mild to moderate and of short duration, while the time of onset was extremely variable. Their incidence was higher in the regimen rifampin (RMP) 900 mg once weekly for ten weeks than when a single dose of RMP 40 mg/kg body weight was given or 1500 mg in one dose followed by one year of dapsone (DDS) 100 mg daily. In multibacillary (MB) leprosy, three regimens were compared: MB-WHO regimen; regimen C, consisting of daily RMP 600 mg, ethionamide (ETH) 500 mg, and DDS or clofazimine (CLO) 100 mg for six months, followed by six months of daily DDS or CLO; and regimen D, identical to regimen C but comprising daily DDS or CLO plus ETH 500 mg during the second semester. Type 1 upgrading reactions occurred more frequently in MB patients and were more severe than in PB patients. They occurred more frequently and were more severe in regimens C and D than in the MB-WHO regimen. CLO 100 mg daily prevented type 1 reactions in MB patients and rendered them less severe. ENL was also more frequent in regimens C and D and was not prevented by CLO in the dosage used. Although there is some correlation between type 1 reactions and the total amount of RMP administered, other aspects of RMP administration.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Adult; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Edema; Erythema Nodosum; Ethionamide; Female; Humans; Leprostatic Agents; Leprosy; Male; Neuritis; Prospective Studies; Rifampin

1986
Antituberculosis chemotherapy.
    American family physician, 1978, Volume: 17, Issue:6

    Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Neuritis; Rifampin; Streptomycin

1978
Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial.
    Leprosy review, 1975, Volume: 46, Issue:2

    Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy; Male; Neuritis; Pilot Projects; Prednisone; Rifampin

1975